Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Breakthrough in Cancer Treatment

Published: Friday, November 15, 2013
Last Updated: Friday, November 15, 2013
Bookmark and Share
New technology will soon enable pathologists to automate the process of marking tissue samples with unprecedented accuracy.

TissueMark, developed by PathXL, analyses the detailed structural patterns in tissue samples and marks the boundaries of potentially cancerous sections for more detailed analysis.   The new software will help accelerate cancer research and discovery, reduce time in drug development and to identify new markers of the disease.

To date, this process has been carried out manually, with sections being hand-marked by pathologists on slides.   An expert pathologist can mark around one hundred samples per day. TissueMark can do the same work in greater detail in ten minutes.  

A study in the Journal of the American Medical Association found that adverse drug reactions were the fourth biggest killer in the US, behind heart disease, cancer and strokes.   TissueMark will play a part in the acceleration of the development of personalized medicine and customized drugs.  

Currently an estimated 25 million tissue samples are analysed annually.  Based on these volumes TissueMark has the potential to save pathologists a combined 250,000 working days of effort per annum and complete the same work with pinpoint accuracy in one fiftieth of the time.

TissueMark’s accuracy, combined with huge increases in the speed of processing, opens the gateway to faster and more accurate diagnoses and the development of treatments.  By truncating the diagnostic process and marking slides with a level of precision that cannot be achieved in manual intervention, TissueMark’s developers believe that there is a real prospect of faster drug discovery and better treatment outcomes.  TissueMark analysis can be carried out remotely and cross-border, enabling more effective collaboration between centers of excellence.

Des Speed, chief executive of PathXL, said: “Manual marking is a relatively slow process that can create significant backlogs.  By removing the bottleneck and delivering greater levels of accuracy we can help accelerate drug development, and the detection and analysis of cancerous tissue.”

Dr Scott Binder, Senior Vice Chair and Director of Pathology Clinical Services at the Department of Pathology & Laboratory Medicine at the University of California at Los Angeles (UCLA), said: “I welcome the development of this new TissueMark technology which will bring new levels of efficiency and accuracy to tissue annotation, freeing pathology professionals worldwide to focus their time and expertise on their most important work, the accurate and timely diagnosis of tumors and other disorders.”

Pathology services worldwide are widely acknowledged to be in short supply.  In some countries there are a handful of pathologists to serve the entire population.  One African country, reputedly, has only one fully qualified pathologist to serve the entire population.  By freeing pathologists of responsibility for marking slides, TissueMark enables these experts to apply their expertise to the next and crucial stage of diagnosis, leading to faster and more accurately prescribed treatments. 

The leap in sophistication and accuracy that TissueMark enables has been described by scientists as being the equivalent of the shift from a freehand outline sketch of a country’s border to a high resolution map of the whole country.

PathXL consulted leading molecular pathologists during the development of TissueMark.  All emphasised that for most molecular assays, such as PCR, it is critical to separate tumor from non-tumor tissue to ensure accurate results.  TissueMark is built with this capability.  As the number of molecular tests increase and the options for patients become more intricate, TissueMark’s speed and reliability will become essential.

Dr James Eshleman, Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine, said:  "Tissue annotation for subsequent molecular analysis is very important in modern molecular diagnostic laboratories."

TissueMark’s first release is built to check for the potential presence of lung, colorectal and breast cancers.  Work is near completion on additional software modules to check for the possible presence of several other forms of cancer, including ovarian and prostate cancer.  The software will be compatible with all major scanning technologies.

Des Speed added: “It is now widely accepted that identifying the molecular signature in individual tumours is vital to the development and selection of targeted therapies.  Technologies, such as TissueMark, are now emerging that enable scientists to achieve this.  Equipping pathologists with our technology will lead to faster, better diagnosis and the potential to make significant savings in time and resource at a time when the burden on medical services is rising rapidly.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!